

Special Issue

Metastatic Pancreatic Ductal Adenocarcinoma

Message from the Guest Editors

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers and is almost always associated with overt or occult metastasis at the time of clinical diagnosis. This malignancy is characterized by a highly complex and heterogeneous tumor microenvironment that contributes to therapy resistance and metastasis. The articles in this Special Issue will focus on various driver genes, signaling pathways, metabolic alterations, and cellular and acellular components that contribute to the metastatic fitness of pancreatic cancer cells. The issue will also focus on various aspects of organotropism and discuss how components of the immune system contribute to metastatic spread. Finally, the articles will also discuss various experimental models being employed to study pancreatic cancer metastasis and preclinical test experimental therapeutics targeting metastatic disease and provide an update on the clinical challenges in combating metastatic PDAC.

Guest Editors

Prof. Dr. Maneesh Jain

Department of Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA

Prof. Dr. Surinder K. Batra

Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA

Deadline for manuscript submissions

closed (13 August 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/58148

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)